Research map: Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity?

Back to the article

Papers in this map

  1. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities · Beate Bittner · 2018 · 443 citations · Cited by this paper
  2. Perspectives on shared decision making related to medications from patients with multiple long-term conditions transitioning from hospital to home: a qualitative study · 2026 · Related
  3. Policies for biosimilar uptake in Europe: An overview · Evelien Moorkens · 2017 · 359 citations · Cited by this paper
  4. Development of a real-world, therapeutic drug monitoring–informed model to predict teicoplanin daily dose in pediatric intensive care unit patients with bacterial infections · 2026 · Related
  5. Key drivers for market penetration of biosimilars in Europe · Cécile Rémuzat · 2017 · 217 citations · Cited by this paper
  6. Comment on “evaluation of high dose post-dialytic versus daily beta-lactam dosing in hemodialysis patients using Monte Carlo simulation” · 2026 · Related
  7. The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review · Liese Barbier · 2020 · 169 citations · Cited by this paper
  8. Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System · 2026 · Related
  9. The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems · Tore Kristian Kvien · 2021 · 156 citations · Cited by this paper
  10. Patient perspectives on atrial fibrillation management and pharmacist roles in outpatient clinics: a qualitative study · 2026 · Related
  11. Patient attitudes and understanding about biosimilars: an international cross-sectional survey · Ira Allen Jacobs · 2016 · 138 citations · Cited by this paper
  12. Active surveillance and risk prediction of piperacillin/tazobactam‑associated hypokalaemia: development and external validation of a clinical nomogram · 2026 · Related
  13. May your drug price be evergreen · Robin Feldman · 2018 · 105 citations · Cited by this paper
  14. Consumers’ experiences and perspectives on reporting adverse drug reactions using digital tools: a qualitative study · 2026 · Related
  15. Uptake of biosimilars for TNF-α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland · B. Duggan · 2021 · 26 citations · Cited by this paper
  16. Grounding clinical supervision in advanced pharmacy practice: a new conceptual model · 2026 · Related
  17. The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review · E. Hillhouse · 2021 · 23 citations · Cited by this paper
  18. A multi-method study of unlicensed medicine risk assessment: a cross-sectional survey of pharmacy procurement leads and policy analysis across NHS trusts in England · 2026 · Related
  19. Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review · Arnold G. Vulto · 2020 · 22 citations · Cited by this paper
  20. Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary · Sophie Shubow · 2022 · 18 citations · Cited by this paper
  21. ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology · Gladys Rodriguez · 2023 · 17 citations · Cited by this paper
  22. Advancing Global Pharmacoequity in Oncology · Parsa Erfani · 2024 · 11 citations · Cited by this paper
  23. Advancing equitable access to innovation in breast cancer · Séamus O’Reilly · 2025 · 10 citations · Cited by this paper
  24. Choosing Wisely in a time of resource constraints · Karen B. Born · 2024 · 9 citations · Cited by this paper
  25. Can biosimilar products be interchangeable? Pharmaceutical perspective in the implementation of biosimilars in oncology · José Cleberson Santos Soares · 2021 · 7 citations · Cited by this paper
  26. Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies · Aqsa Safdar · 2021 · 7 citations · Cited by this paper
  27. Safety of Switching from a Reference Biologic to Its Biosimilar: A Systematic Review and Meta-Analysis · Sarah Saad Aljahili · 2025 · 7 citations · Cited by this paper
  28. Optimising oncology drug expenditure in Ireland · Ruth Kieran · 2024 · 6 citations · Cited by this paper
  29. Leveraging the holistic benefits of biosimilars in Europe – part 2: how payers can safeguard the future of a healthy biosimilar market environment · Jorge Mestre‐Ferrandiz · 2024 · 5 citations · Cited by this paper
  30. Learnings from cross-border biosimilar pricing policies in Europe · Steven Simoens · 2024 · 5 citations · Cited by this paper
  31. The potential role of biosimilars in healthcare sustainability in Latin America · Rony Schaffel · 2025 · 4 citations · Cited by this paper
  32. Mapping Intellectual Property Abuses in the Pharmaceutical Field · S. Sean Tu · 2025 · 3 citations · Cited by this paper
  33. An evaluation of the utilisation of biosimilar monoclonal antibody drugs in Ireland and barriers to their usage · Kate E. Coakley · 2024 · 2 citations · Cited by this paper
  34. Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability · Ivar Veszelei · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)